Free tool
FAERS Monitor: Labetalol Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213330 or its brand name (Labetalol Hydrochloride, Labetalol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
13,484
Serious
10,245
76% of reports
Hospitalization
5,112
Death reported
1,375
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,060
- maternal exposure during pregnancy1,001
- foetal exposure during pregnancy976
- hypertension767
- premature baby752
- off label use726
- exposure during pregnancy672
- chronic kidney disease646
- acute kidney injury645
- fatigue616
- renal failure581
- nausea555
- headache519
- premature delivery516
- dyspnoea499
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 59 |
| 2005 | 137 |
| 2006 | 66 |
| 2007 | 42 |
| 2008 | 44 |
| 2009 | 54 |
| 2010 | 74 |
| 2011 | 197 |
| 2012 | 213 |
| 2013 | 438 |
| 2014 | 709 |
| 2015 | 751 |
| 2016 | 757 |
| 2017 | 944 |
| 2018 | 1,068 |
| 2019 | 1,223 |
| 2020 | 1,144 |
| 2021 | 1,100 |
| 2022 | 1,017 |
| 2023 | 908 |
| 2024 | 956 |
| 2025 | 857 |
| 2026 | 726 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,675 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| premature deliverySignal | 516 | 52.2 | 47.9 | 25,043 |
| premature babySignal | 752 | 39.9 | 37.2 | 27,844 |
| foetal exposure during pregnancySignal | 976 | 18.9 | 17.8 | 16,436 |
| maternal exposure during pregnancySignal | 1,001 | 17.7 | 16.7 | 15,652 |
| exposure during pregnancySignal | 672 | 17.0 | 15.8 | 10,050 |
| chronic kidney diseaseSignal | 646 | 13.4 | 12.4 | 7,343 |
| renal failureSignal | 581 | 6.9 | 6.3 | 2,903 |
| acute kidney injurySignal | 645 | 6.6 | 6.1 | 3,067 |
| hypertensionSignal | 767 | 5.7 | 5.3 | 2,962 |
| dyspnoea | 499 | 1.4 | 1.3 | 52 |
| off label use | 726 | 1.3 | 1.2 | 50 |
| headache | 519 | 1.3 | 1.2 | 35 |
| drug ineffective | 1,060 | 1.3 | 1.2 | 58 |
| fatigue | 616 | 1.2 | 1.1 | 28 |
| nausea | 555 | 1.1 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.